https://www.pharmaradar360.com/article/solartm-gi-dae44a3754bab86cPharma Surgeen2026-07-16T12:00:00.000ZSolar™ GIhttps://www.pharmaradar360.com/article/single-use-sterile-bioprocessing-tools-2e820dff4d0ef8b6Pharma Surgeen2026-07-16T11:09:46.000ZSingle-Use Sterile Bioprocessing Toolshttps://www.pharmaradar360.com/article/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-ac8232b26f2a9208Pharma Surgeen2026-07-16T11:05:00.000ZRelmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026https://www.pharmaradar360.com/article/european-biotech-act-advances-biotechnology-innovation-5a48e492d66c07caPharma Surgeen2026-07-16T11:03:07.000ZEuropean Biotech Act Advances Biotechnology Innovationhttps://www.pharmaradar360.com/article/fedex-life-sciences-launches-to-support-pharmaceutical-logistics-eb60a6b5c3d54a1cPharma Surgeen2026-07-16T11:00:11.000ZFedEx Life Sciences launches to support pharmaceutical logisticshttps://www.pharmaradar360.com/article/moderna-trial-tests-cancer-therapy-encoding-seven-antigens-bbd9868fc112b037Pharma Surgeen2026-07-16T11:00:00.000ZModerna Trial Tests Cancer Therapy Encoding Seven Antigenshttps://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-16T10:55:41.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/eli-lilly-to-buy-psychedelics-maker-ataibeckley-for-2-8-billion-as-experimental-c83ccd6c6c9de6e5Pharma Surgeen2026-07-16T10:45:53.000ZEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionhttps://www.pharmaradar360.com/article/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-f513ffd9e62e44adPharma Surgeen2026-07-16T10:45:00.000ZMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemiahttps://www.pharmaradar360.com/article/ataibeckley-s-bpl-003-shows-months-of-effects-after-2-hour-visits-c7ddce453dd42815Pharma Surgeen2026-07-16T10:45:00.000ZAtaiBeckley’s BPL-003 Shows Months of Effects After 2-Hour Visitshttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-to-advance-therapies-for-treatment-resistant-depres-f3af133918fbe32cPharma Surgeen2026-07-16T10:45:00.000ZLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionshttps://www.pharmaradar360.com/article/1-2026-4f0a4b02170c7516Pharma Surgeen2026-07-16T10:38:07.000ZΜΗΣΥΦΑ 1ου Τριμήνου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-del-mercado-de-determinadas-canulas-guedel-de-un-01a6419ed76e2626Pharma Surgeen2026-07-16T10:33:45.000ZLa AEMPS informa de la retirada del mercado de determinadas cánulas Guedel de una sola piezahttps://www.pharmaradar360.com/article/datroway-ec8ad2f1de7fa374Pharma Surgeen2026-07-16T10:33:28.000ZDatrowayhttps://www.pharmaradar360.com/article/biomarin-bmrn-wins-fda-review-for-voxzogo-full-approval-in-achondroplasia-40dbb7257304ea50Pharma Surgeen2026-07-16T10:31:37.000ZBioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasiahttps://www.pharmaradar360.com/article/amylyx-nears-pivotal-endocrine-drug-study-readout-ff39615c409c8942Pharma Surgeen2026-07-16T10:30:59.000ZAmylyx nears pivotal endocrine drug study readouthttps://www.pharmaradar360.com/article/italy-s-angelini-pharma-completes-4-1-billion-state-backed-takeover-of-catalyst-01b453d29b162daePharma Surgeen2026-07-16T10:20:23.000ZItaly's Angelini Pharma completes $4.1 billion state-backed takeover of Catalysthttps://www.pharmaradar360.com/article/biomarkers-in-nephrology-research-from-exploratory-to-decision-making-tools-2290c940259f3fc1Pharma Surgeen2026-07-16T10:17:07.000ZBiomarkers in Nephrology Research: From Exploratory to Decision-Making Toolshttps://www.pharmaradar360.com/article/annex-1-sterilisation-why-pharma-packaging-strategy-is-changing-d0874f189c71fd8bPharma Surgeen2026-07-16T10:17:07.000ZAnnex 1 sterilisation: Why pharma packaging strategy is changinghttps://www.pharmaradar360.com/article/malaria-prevention-guidelines-for-travellers-from-the-uk-2026-bfdb8582fd85690ePharma Surgeen2026-07-16T10:08:15.000ZMalaria prevention guidelines for travellers from the UK 2026https://www.pharmaradar360.com/article/biomed-industries-presents-promising-phase-2-3-clinical-results-of-na-921-for-re-6af9732cd4b928fbPharma Surgeen2026-07-16T10:00:00.000ZBiomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026https://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-asthma-therapy-0b293e653e6af0a5Pharma Surgeen2026-07-16T09:59:04.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-16T09:50:26.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/j-j-tops-25-billion-quarter-lifts-2026-outlook-bece073262a14099Pharma Surgeen2026-07-16T09:47:32.000ZJ&J tops $25 billion quarter, lifts 2026 outlookhttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-16T09:44:51.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-seis-lotes-del-medicamento-veterinario-moduli-bcd4952599605e76Pharma Surgeen2026-07-16T09:41:36.000ZLa AEMPS informa de la retirada de seis lotes del medicamento veterinario Modulis 100mg/ml solución oral para perroshttps://www.pharmaradar360.com/article/modulis-100-mg-ml-solucion-oral-para-perros-no-3178-esp-229f003566a30325Pharma Surgeen2026-07-16T09:40:34.000ZMODULIS 100 MG/ML SOLUCION ORAL PARA PERROS (Nº 3178 ESP)https://www.pharmaradar360.com/article/biotech-venture-funding-roars-back-272491de7fff8b98Pharma Surgeen2026-07-16T09:30:00.000ZBiotech Venture Funding Roars Backhttps://www.pharmaradar360.com/article/bayer-adds-a-spine-to-modularity-for-scale-without-disruption-7d6fd16e3046de5fPharma Surgeen2026-07-16T09:24:30.000ZBayer Adds A Spine To Modularity For Scale Without Disruptionhttps://www.pharmaradar360.com/article/nihr-sphr-transdisciplinary-fellowships-in-public-health-research-2026-1f2621f6ecd2812aPharma Surgeen2026-07-16T09:23:29.000ZNIHR SPHR Transdisciplinary Fellowships in public health research 2026https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-shows-high-growth-momentum-with-perfect-minervini-tr-3623183038eb9a0bPharma Surgeen2026-07-16T09:20:28.000ZKrystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setuphttps://www.pharmaradar360.com/article/vogenx-joins-the-ipo-queue-to-fund-phase-2-stage-metabolic-drug-3ea5708412500b7dPharma Surgeen2026-07-16T09:19:05.000ZVogenx joins the IPO queue to fund phase 2-stage metabolic drughttps://www.pharmaradar360.com/article/global-penny-stocks-guizhou-yibai-pharmaceutical-and-2-more-to-watch-a1ee61041a90e090Pharma Surgeen2026-07-16T09:15:54.000ZGlobal Penny Stocks: Guizhou Yibai Pharmaceutical And 2 More To Watchhttps://www.pharmaradar360.com/article/top-five-global-pharma-signs-deal-to-test-kangstem-s-hair-follicle-organoids-for-5ffaa0e135f070f4Pharma Surgeen2026-07-16T09:03:49.000ZTop-five global pharma signs deal to test Kangstem’s hair follicle organoids for hair-loss drugshttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-press-release-pursuant-to-article-36-of-the-is-0643304fbc750a67Pharma Surgeen2026-07-16T08:54:00.000ZOn behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 36 of the Issuers’ Regulationhttps://www.pharmaradar360.com/article/small-molecules-still-do-the-heavy-lifting-in-drug-development-029381492555c8e2Pharma Surgeen2026-07-16T08:48:45.000ZSmall molecules still do the heavy lifting in drug developmenthttps://www.pharmaradar360.com/article/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-s-b46c9c5c900a9ce9Pharma Surgeen2026-07-16T08:35:04.000ZKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/preparing-for-the-pharma-fraud-enforcement-surge-e4d2970b84515fcePharma Surgeen2026-07-16T08:32:59.000ZPreparing for the pharma fraud enforcement surgehttps://www.pharmaradar360.com/article/geodis-strengthens-pharmaceutical-logistics-capabilities-in-poland-187bbe9d9d82c461Pharma Surgeen2026-07-16T08:32:41.000ZGEODIS strengthens pharmaceutical logistics capabilities in Polandhttps://www.pharmaradar360.com/article/framework-agreements-between-the-department-of-health-and-social-care-and-its-ar-10908850a6438af4Pharma Surgeen2026-07-16T08:30:06.000ZFramework agreements between the Department of Health and Social Care and its arm’s length bodieshttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-16T08:30:05.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/bloodborne-viruses-managing-risk-in-bomb-blast-victims-adf8b25c8152aab9Pharma Surgeen2026-07-16T08:30:01.000ZBloodborne viruses: managing risk in bomb blast victimshttps://www.pharmaradar360.com/article/framework-agreement-between-dhsc-and-the-human-fertilisation-and-embryology-auth-2a0fe3c241cea627Pharma Surgeen2026-07-16T08:30:00.000ZFramework agreement between DHSC and the Human Fertilisation and Embryology Authority: 2026 to 2029https://www.pharmaradar360.com/article/testing-the-hypothesis-a-focused-pilot-for-ai-in-healthcare-99ed98de69be6a2dPharma Surgeen2026-07-16T08:17:35.000ZTesting the hypothesis: a focused pilot for AI in healthcarehttps://www.pharmaradar360.com/article/care-workers-to-be-represented-in-fair-pay-agreements-f15c5f1f347b1e65Pharma Surgeen2026-07-16T08:15:06.000ZCare workers to be represented in Fair Pay Agreementshttps://www.pharmaradar360.com/article/can-cah-sustain-growth-on-booming-pharmaceutical-specialty-segment-9dce455c9008daf3Pharma Surgeen2026-07-16T08:09:04.000ZCan CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?https://www.pharmaradar360.com/article/us-biotech-biogen-hires-spur-therapeutics-ceo-as-next-legal-chief-51a1cae8dcf9b693Pharma Surgeen2026-07-16T07:56:00.000ZUS biotech Biogen hires Spur Therapeutics CEO as next legal chiefhttps://www.pharmaradar360.com/article/3-high-growth-mining-and-biotech-stocks-with-healthy-balance-sheets-11ac602cd64257cdPharma Surgeen2026-07-16T07:38:12.000Z3 High Growth Mining And Biotech Stocks With Healthy Balance Sheetshttps://www.pharmaradar360.com/article/kosdaq-listed-biotech-alteogen-slides-amid-rival-technology-concerns-dda02d7b60b4008ePharma Surgeen2026-07-16T06:53:41.000ZKOSDAQ-listed biotech Alteogen slides amid rival technology concernshttps://www.pharmaradar360.com/article/empowering-fine-chemicals-through-technological-innovation-wisdom-pharmaceutical-78003a34b14d2cf2Pharma Surgeen2026-07-16T06:43:49.000ZEmpowering Fine Chemicals through Technological Innovation–Wisdom Pharmaceutical Connects Global Pharmaceutical and Agrochemical Markets - ChemNethttps://www.pharmaradar360.com/article/niagen-bioscience-inc-nage-discusses-strategic-expansion-into-pharmaceutical-dev-d3a284e98c609ab3Pharma Surgeen2026-07-16T06:30:45.000ZNiagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program - Slideshow (NASDAQ:NAGE) 2026-07-16https://www.pharmaradar360.com/article/89478ca09cf0bcc8Pharma Surgeen2026-07-16T06:06:08.000ZΔήλωση Αποθεμάτων Φαρμάκων Ανθρώπινης Χρήσηςhttps://www.pharmaradar360.com/article/usc-alfred-e-mann-school-of-pharmacy-and-pharmaceutical-sciences-787f3cac2ac46793Pharma Surgeen2026-07-16T05:58:11.000ZUSC Alfred E. Mann School of Pharmacy and Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/j-j-raises-fy26-outlook-following-positive-q2-bf5ed898f58b39e8Pharma Surgeen2026-07-16T04:29:51.000ZJ&J raises FY26 outlook following positive Q2https://www.pharmaradar360.com/article/chinese-fund-managers-increase-biotech-holdings-in-hong-kong-amid-attractive-val-2a34a2cb093c3814Pharma Surgeen2026-07-16T03:11:00.000ZChinese Fund Managers Increase Biotech Holdings in Hong Kong Amid Attractive Valuations - News and Statisticshttps://www.pharmaradar360.com/article/mainland-funds-boost-stakes-in-hong-kong-listed-biotech-amid-value-dislocation-1f46de8fc253cb96Pharma Surgeen2026-07-16T03:03:20.000ZMainland funds boost stakes in Hong Kong-listed biotech amid value dislocationhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-vorzzz-cef91b05fad6e791Pharma Surgeen2026-07-16T03:00:00.000Z[SHINSA]English Translation of Review Report: Vorzzzhttps://www.pharmaradar360.com/article/st-pharm-s-hiv-drug-candidate-shows-97-5-viral-load-reduction-in-phase-2a-trial-77f4cdd99f2580e9Pharma Surgeen2026-07-16T02:46:00.000ZST Pharm's HIV Drug Candidate Shows 97.5% Viral Load Reduction in Phase 2a Trial, Boosting Licensing Prospectshttps://www.pharmaradar360.com/article/loss-making-noile-immune-biotech-inc-tse-4893-expected-to-breakeven-in-the-mediu-c5d0de1aa5a6359ePharma Surgeen2026-07-16T02:20:28.000ZLoss-Making Noile-Immune Biotech Inc. (TSE:4893) Expected To Breakeven In The Medium-Termhttps://www.pharmaradar360.com/article/the-next-rare-earths-why-us-fears-another-chinese-manufacturing-advantage-9f62815539d161e5Pharma Surgeen2026-07-16T01:59:20.000ZThe next rare earths? Why US fears another Chinese manufacturing advantagehttps://www.pharmaradar360.com/article/connecticut-receiving-388k-from-multi-state-settlement-with-glenmark-pharmaceuti-13f13fec529d1569Pharma Surgeen2026-07-16T01:49:00.000ZConnecticut receiving $388K from multi-state settlement with Glenmark pharmaceutical companyhttps://www.pharmaradar360.com/article/senate-bill-seeks-to-curb-us-reliance-on-china-in-drug-industry-a8c57f2d4f1bcca4Pharma Surgeen2026-07-16T00:38:29.000ZSenate bill seeks to curb US reliance on China in drug industryhttps://www.pharmaradar360.com/article/braveheart-bio-attovia-join-growing-pipeline-of-biotech-ipos-07a203c2bed21675Pharma Surgeen2026-07-16T00:36:00.000ZBraveheart Bio, Attovia Join Growing Pipeline Of Biotech IPOshttps://www.pharmaradar360.com/article/mfn-drug-pricing-what-pharmaceutical-manufacturers-need-to-know-about-their-inte-1eb1952c48da10eaPharma Surgeen2026-07-16T00:29:44.000ZMFN Drug Pricing: What Pharmaceutical Manufacturers Need To Know About Their International Agreements (Video)https://www.pharmaradar360.com/article/algorae-names-nasdaq-pharmaceutical-chairman-to-strengthen-board-d41dee70cc791708Pharma Surgeen2026-07-16T00:11:22.000ZAlgorae names Nasdaq pharmaceutical chairman to strengthen boardhttps://www.pharmaradar360.com/article/otsuka-foods-to-launch-new-my-size-plus-support-w-double-delivering-nutritional-abaad7f259228c45Pharma Surgeen2026-07-16T00:00:00.000ZOtsuka Foods to Launch New “My Size Plus Support W (Double)” Delivering Nutritional Support and Salt Control in One Product Available at Dispensing Pharmacies and Select Drugstores across Japan on July 31, 2026https://www.pharmaradar360.com/article/thousands-eligible-for-new-chronic-heart-failure-treatment-following-nice-recomm-6eaada26f019210ePharma Surgeen2026-07-16T00:00:00.000ZThousands eligible for new chronic heart failure treatment following NICE recommendationhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-16T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-f79a5f4ea34ff840Pharma Surgeen2026-07-16T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-1e75f37325500bc8Pharma Surgeen2026-07-16T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-f4a0aeec504b078dPharma Surgeen2026-07-16T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1c6f976fc036e64ePharma Surgeen2026-07-16T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-0eae370776c342ddPharma Surgeen2026-07-16T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-033a4af77ac7d1dfPharma Surgeen2026-07-16T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-6703234e0fba5735Pharma Surgeen2026-07-16T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-0c164e42823e647fPharma Surgeen2026-07-16T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-4751526d33ccdeacPharma Surgeen2026-07-16T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b67e4602292943c5Pharma Surgeen2026-07-16T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fd6c7213fbdeaeacPharma Surgeen2026-07-16T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-8b38c495a81bc2a0Pharma Surgeen2026-07-16T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-db4afeda2ce1c082Pharma Surgeen2026-07-16T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-7501e8a73c404666Pharma Surgeen2026-07-16T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/order-under-sections-362-and-365-of-the-public-health-service-act-continuing-the-51ddf79b7eb02fb9Pharma Surgeen2026-07-16T00:00:00.000ZOrder Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Existshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-d74fd2dc7c11ebf2Pharma Surgeen2026-07-16T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/medicaid-and-children-s-health-insurance-program-chip-generic-information-collec-c4441bb30ddf7591Pharma Surgeen2026-07-16T00:00:00.000ZMedicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/request-for-information-clinical-laboratory-improvement-amendments-of-1988-clia-03d560f0394d578bPharma Surgeen2026-07-16T00:00:00.000ZRequest for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulationshttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-method-of-manufacturing-papillo-5ae4948e432e3383Pharma Surgeen2026-07-16T00:00:00.000ZGovernment Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)https://www.pharmaradar360.com/article/government-owned-invention-available-for-license-selective-expansion-of-engineer-c88ae775347c6da1Pharma Surgeen2026-07-16T00:00:00.000ZGovernment Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapyhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-chimeric-antigen-receptors-targ-c73e5bc8759fd75dPharma Surgeen2026-07-16T00:00:00.000ZGovernment Owned Invention Available for License: Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptorhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-fddb2f2a22cd969fPharma Surgeen2026-07-16T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-cy-2027-payment-policies-under-the-physician-fee-64f1dc34c8c5f8b2Pharma Surgeen2026-07-16T00:00:00.000ZMedicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Programhttps://www.pharmaradar360.com/article/patient-safety-organizations-expired-listing-for-the-informed-patient-safety-org-1378b1b2a0cce240Pharma Surgeen2026-07-16T00:00:00.000ZPatient Safety Organizations: Expired Listing for the Informed Patient Safety Organization (IPSO)https://www.pharmaradar360.com/article/meeting-of-the-advisory-board-on-radiation-and-worker-health-national-institute-3ec14233dc1d3649Pharma Surgeen2026-07-16T00:00:00.000ZMeeting of the Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Healthhttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-child-and-family-services-52f2f7fe2a147e44Pharma Surgeen2026-07-16T00:00:00.000ZSubmission for Office of Management and Budget Review; Child and Family Services Plan, Annual Progress and Services Report, and Annual Budget Expenses Request and Estimated Expenditures (Child and Family Services-101)https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-catalent-greenville-inc-2eaf5ba948afbf4fPharma Surgeen2026-07-16T00:00:00.000ZImporter of Controlled Substances Application: Catalent Greenville, Inc.https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-unither-manufacturing-llc-572a5054f869d1d0Pharma Surgeen2026-07-16T00:00:00.000ZImporter of Controlled Substances Application: Unither Manufacturing LLChttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-ampac-fine-chemicals-llc-134bdf63d8528e1aPharma Surgeen2026-07-16T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals LLChttps://www.pharmaradar360.com/article/process-for-fda-data-requests-to-inform-certain-over-the-counter-monograph-drug-3d10ecfff0fa44e6Pharma Surgeen2026-07-16T00:00:00.000ZProcess for FDA Data Requests To Inform Certain Over-the-Counter Monograph Drug Activities; Procedurehttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-catalent-cts-llc-3f06039010cf1722Pharma Surgeen2026-07-16T00:00:00.000ZImporter of Controlled Substances Application: Catalent CTS, LLChttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-evaluation-of-the-next-gen-19cd3312fdbe0717Pharma Surgeen2026-07-16T00:00:00.000ZSubmission for Office of Management and Budget Review; Evaluation of the Next Generation Child Support Employment Services Demonstrationhttps://www.pharmaradar360.com/article/clinical-and-health-system-factors-associated-with-antiretroviral-therapy-adhere-8197c2bb70004630Pharma Surgeen2026-07-16T00:00:00.000ZClinical and health system factors associated with antiretroviral therapy adherence among people living with HIV and AIDS: cross-sectional survey insights from three ART facilities in Tamale, Ghanahttps://www.pharmaradar360.com/article/natural-products-in-modern-drug-discovery-advances-challenges-and-emerging-techn-ab4f3a55f2fb173cPharma Surgeen2026-07-16T00:00:00.000ZNatural Products in Modern Drug Discovery: Advances, Challenges and Emerging Technologieshttps://www.pharmaradar360.com/article/combined-aerobic-resistance-training-and-taurine-supplementation-reduce-asprosin-fa3ca0a96804f127Pharma Surgeen2026-07-16T00:00:00.000ZCombined Aerobic–Resistance Training and Taurine Supplementation Reduce Asprosin and Elevate Spexin in Men with Obesity: A 12-Week Supplement-Blinded, Randomized Controlled Trialhttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-of-myval-vs-acurate-neo-valves-in-tavr-a-single-8230bbd9710fe587Pharma Surgeen2026-07-16T00:00:00.000ZComparison of Clinical Outcomes of Myval vs. Acurate Neo Valves in TAVR: A Single-Center Experiencehttps://www.pharmaradar360.com/article/preoperative-urodynamics-in-pelvic-organ-prolapse-to-identify-postoperative-inco-880fd1e54052d9daPharma Surgeen2026-07-16T00:00:00.000ZPreoperative Urodynamics in Pelvic Organ Prolapse to Identify Postoperative Incontinencehttps://www.pharmaradar360.com/article/transcatheter-versus-mechanical-and-bioprosthetic-surgical-aortic-valve-replacem-5694977df28d22d0Pharma Surgeen2026-07-16T00:00:00.000ZTranscatheter Versus Mechanical and Bioprosthetic Surgical Aortic Valve Replacement in Retrospective Patient Cohorts with Aortic Stenosis <75 Yearshttps://www.pharmaradar360.com/article/association-of-hyperuricemia-with-the-onset-and-progression-of-type-2-diabetic-r-15eae375077e3199Pharma Surgeen2026-07-16T00:00:00.000ZAssociation of Hyperuricemia with the Onset and Progression of Type 2 Diabetic Retinopathyhttps://www.pharmaradar360.com/article/comparison-of-efficacy-and-safety-of-denosumab-with-eldecalcitol-or-native-vitam-11916a4cba406205Pharma Surgeen2026-07-16T00:00:00.000ZComparison of Efficacy and Safety of Denosumab with Eldecalcitol or Native Vitamin D in Postmenopausal Chinese Women with Osteoporosis (ESCORT): A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/examining-clinical-educators-readiness-for-artificial-intelligence-in-medical-ed-272381f7ac17f664Pharma Surgeen2026-07-16T00:00:00.000ZExamining Clinical Educators’ Readiness for Artificial Intelligence in Medical Education: An Exploratory Qualitative Studyhttps://www.pharmaradar360.com/article/n-acetylcysteine-in-endometriosis-a-systematic-review-of-biological-rationale-an-29fd91f09f71ea68Pharma Surgeen2026-07-16T00:00:00.000ZN-Acetylcysteine in Endometriosis: A Systematic Review of Biological Rationale and Clinical Evidencehttps://www.pharmaradar360.com/article/from-online-collaboration-to-clinical-insight-identifying-heterotopic-ossificati-5f394ef10c27d83dPharma Surgeen2026-07-16T00:00:00.000ZFrom online collaboration to clinical insight: identifying heterotopic ossification through a global hernia surgery networkhttps://www.pharmaradar360.com/article/clinical-characteristics-and-associated-factors-of-airway-allergic-diseases-amon-7f1e8f2c1e4df1c5Pharma Surgeen2026-07-16T00:00:00.000ZClinical characteristics and associated factors of airway allergic diseases among children: a cross-sectional study in a district of Beijinghttps://www.pharmaradar360.com/article/assessing-the-relationship-between-body-mass-index-and-influenza-like-illness-ri-9d598d44327cb533Pharma Surgeen2026-07-16T00:00:00.000ZAssessing the relationship between body mass index and influenza-like illness risk and symptom severity among military health system beneficiaries vaccinated against influenza: a pooled prospective cohort study from a randomized trialhttps://www.pharmaradar360.com/article/harmonizing-mind-acupuncture-combined-with-nicotine-replacement-therapy-for-toba-1016f63c2054b9c5Pharma Surgeen2026-07-16T00:00:00.000ZHarmonizing mind acupuncture combined with nicotine replacement therapy for tobacco use disorder: a protocol for a pragmatic randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-outcomes-of-atrial-tachyarrhythmia-hospitalizations-with-and-without-pr-bfbca6e075f4111bPharma Surgeen2026-07-16T00:00:00.000ZClinical outcomes of atrial tachyarrhythmia hospitalizations with and without prior thoracic irradiationhttps://www.pharmaradar360.com/article/decoding-drug-resistance-and-apoptosis-in-biliary-tract-cancers-using-3d-tumor-m-f1882ff403485718Pharma Surgeen2026-07-16T00:00:00.000ZDecoding drug resistance and apoptosis in biliary tract cancers using 3D tumor modelshttps://www.pharmaradar360.com/article/association-of-early-supplemental-parenteral-nutrition-with-clinical-outcomes-in-b3fa44df63b054a1Pharma Surgeen2026-07-16T00:00:00.000ZAssociation of Early Supplemental Parenteral Nutrition with Clinical Outcomes in Patients with Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/clinical-characteristics-of-acute-chikungunya-cases-at-iahs-hospital-c7ed5940a10862efPharma Surgeen2026-07-16T00:00:00.000ZClinical Characteristics of Acute Chikungunya Cases at IAHS Hospitalhttps://www.pharmaradar360.com/article/bridging-periodontitis-and-clonal-hematopoiesis-implications-for-solid-tumor-met-e80b709b3ad681f0Pharma Surgeen2026-07-16T00:00:00.000ZBridging periodontitis and clonal hematopoiesis: implications for solid tumor metastasis, clinical trial design, and microbiome dynamics. Comment on: "Ligature-induced periodontitis promotes Dnmt3aR878H-driven clonal hematopoiesis"https://www.pharmaradar360.com/article/acne-care-online-protocol-for-a-randomised-trial-of-a-digital-behaviour-change-i-fac8e266a453cd0dPharma Surgeen2026-07-16T00:00:00.000ZAcne Care Online: protocol for a randomised trial of a digital behaviour change intervention to improve acne-related quality of life amongst 13-25 year oldshttps://www.pharmaradar360.com/article/artificial-intelligence-in-endodontic-decision-making-hallucinations-and-emergin-a126f217c7b53da7Pharma Surgeen2026-07-16T00:00:00.000ZArtificial intelligence in endodontic decision-making: hallucinations and emerging challenges for clinical practicehttps://www.pharmaradar360.com/article/efficacy-and-safety-of-postoperative-analgesia-for-intercostal-catheterization-g-455069bfd794a25ePharma Surgeen2026-07-16T00:00:00.000ZEfficacy and safety of postoperative analgesia for intercostal catheterization guided by thoracoscopy in single port thoracoscopic surgery: a prospective randomized controlled trialhttps://www.pharmaradar360.com/article/an-algorithmic-process-to-develop-clinical-practice-guideline-recommendations-ba-c8878972e9b95d4dPharma Surgeen2026-07-16T00:00:00.000ZAn algorithmic process to develop clinical practice guideline recommendations based on meta-analyses of the relevant evidencehttps://www.pharmaradar360.com/article/noninvasive-assessment-of-arterial-compliance-and-lumen-pressure-in-human-caroti-e052ef5de579ecfePharma Surgeen2026-07-16T00:00:00.000ZNoninvasive Assessment of Arterial Compliance and Lumen Pressure in Human Carotid Arteries Using Physics-Informed Neural Networks and Ultrasound Imaging: A Clinical Feasibility Studyhttps://www.pharmaradar360.com/article/iterative-feedback-refinement-for-faithful-structured-clinical-note-representati-f3267ca886e9a9adPharma Surgeen2026-07-16T00:00:00.000ZIterative Feedback--Refinement for Faithful Structured Clinical-Note Representationhttps://www.pharmaradar360.com/article/cement-compression-device-for-cemented-total-knee-arthroplasty-6931c96ea82a13f5Pharma Surgeen2026-07-16T00:00:00.000ZCement compression device for cemented total knee arthroplastyhttps://www.pharmaradar360.com/article/clinical-study-on-the-3d-morphology-and-mechanical-factors-of-lumbar-facet-joint-ed5ce2111a49a74cPharma Surgeen2026-07-16T00:00:00.000ZClinical study on the 3D morphology and mechanical factors of lumbar facet joints in patients with degenerative lumbar spondylolisthesishttps://www.pharmaradar360.com/article/idiopathic-mesenteric-phlebosclerosis-associated-with-long-term-herbal-medicine-39bf111eb76629a3Pharma Surgeen2026-07-16T00:00:00.000ZIdiopathic mesenteric phlebosclerosis associated with long-term herbal medicine use: A case reporthttps://www.pharmaradar360.com/article/eccentric-semilunar-penetrating-keratoplasty-for-peripheral-corneal-perforation-d40fd4517f4e80b9Pharma Surgeen2026-07-16T00:00:00.000ZEccentric semilunar penetrating keratoplasty for peripheral corneal perforation following chemical eye injury: A case reporthttps://www.pharmaradar360.com/article/long-term-survival-in-patients-with-primary-malignant-brain-tumors-after-postope-55fcb04504bef176Pharma Surgeen2026-07-16T00:00:00.000ZLong-term survival in patients with primary malignant brain tumors after postoperative home hydrogen inhalation: Three case reportshttps://www.pharmaradar360.com/article/clinical-and-electroencephalographic-characteristics-of-epilepsy-following-hypox-7b8674b64aec8401Pharma Surgeen2026-07-16T00:00:00.000ZClinical and electroencephalographic characteristics of epilepsy following hypoxic-ischemic encephalopathy: a retrospective analysishttps://www.pharmaradar360.com/article/correction-comparing-xenium-5k-and-visium-hd-data-from-identical-tissue-slide-at-392e2dd9091b59f0Pharma Surgeen2026-07-16T00:00:00.000ZCorrection: Comparing Xenium 5K and Visium HD data from identical tissue slide at a pathological perspectivehttps://www.pharmaradar360.com/article/anal-cancer-screening-introduction-into-routine-clinical-care-for-key-population-580cdd05b7e6fcb3Pharma Surgeen2026-07-16T00:00:00.000ZAnal cancer screening: introduction into routine clinical care for key populationshttps://www.pharmaradar360.com/article/the-effect-of-preoperative-chewing-gum-on-anxiety-and-postoperative-sore-throat-dbbf65e8da646a18Pharma Surgeen2026-07-16T00:00:00.000ZThe Effect of Preoperative Chewing Gum on Anxiety and Postoperative Sore Throat in Patients Using a Laryngeal Mask Airway: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/how-ai-reshapes-clinical-knowledge-a-knowledge-lifecycle-model-of-ai-adoption-in-3e44d6681be750a7Pharma Surgeen2026-07-16T00:00:00.000ZHow AI reshapes clinical knowledge: a knowledge lifecycle model of AI adoption in hearing carehttps://www.pharmaradar360.com/article/acquired-methemoglobinemia-from-intentional-exposure-to-uncommon-agrochemicals-a-19ec700b5c240c76Pharma Surgeen2026-07-16T00:00:00.000ZAcquired methemoglobinemia from intentional exposure to uncommon agrochemicals: a case serieshttps://www.pharmaradar360.com/article/correction-too-stressed-to-cope-a-multiple-mediation-analysis-of-social-bonds-sl-31d3d3acfc72e68ePharma Surgeen2026-07-16T00:00:00.000ZCorrection: Too stressed to cope? A multiple mediation analysis of social bonds, sleep quality, and sleep disturbances in relation to prescription drug use among Chinese high school seniorshttps://www.pharmaradar360.com/article/multifaceted-roles-of-isthmin-1-in-health-and-disease-mechanism-and-therapeutic-7d99eb4a14010fd3Pharma Surgeen2026-07-16T00:00:00.000ZMultifaceted roles of Isthmin-1 in health and disease: mechanism and therapeutic interventionhttps://www.pharmaradar360.com/article/repurposing-the-antiplatelet-drug-prasugrel-for-parkinson-s-disease-evidence-of-ca5e5844d11b3d9fPharma Surgeen2026-07-16T00:00:00.000ZRepurposing the antiplatelet drug prasugrel for Parkinson’s disease: evidence of neuroprotective effects and proteomic profileshttps://www.pharmaradar360.com/article/asciminib-monotherapy-in-patients-with-bcr-abl1-t315i-mutated-chronic-phase-chro-b097b6e97f5a52faPharma Surgeen2026-07-16T00:00:00.000ZAsciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final resultshttps://www.pharmaradar360.com/article/team-science-training-needs-and-preferences-for-clinical-research-professionals-d55403403383a61bPharma Surgeen2026-07-16T00:00:00.000ZTeam Science Training Needs and Preferences for Clinical Research Professionalshttps://www.pharmaradar360.com/article/sudden-memory-loss-e49beb3fea03c44fPharma Surgeen2026-07-16T00:00:00.000ZSudden Memory Losshttps://www.pharmaradar360.com/article/incontinence-and-fatigue-ceb891240fba2e45Pharma Surgeen2026-07-16T00:00:00.000ZIncontinence and Fatiguehttps://www.pharmaradar360.com/article/progressive-imbalance-f6ce88b41111683cPharma Surgeen2026-07-16T00:00:00.000ZProgressive Imbalancehttps://www.pharmaradar360.com/article/progressive-fatigue-c01a23e3aff631e5Pharma Surgeen2026-07-16T00:00:00.000ZProgressive Fatiguehttps://www.pharmaradar360.com/article/the-association-between-psychodermatological-behaviors-economic-burden-and-perce-7c09821946326903Pharma Surgeen2026-07-16T00:00:00.000ZThe Association Between Psychodermatological Behaviors, Economic Burden, and Perception of Clinical Severity in Telogen Effluvium: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/histological-spectrum-and-determinants-of-survival-in-malignant-mesothelioma-mul-15328eafc223890dPharma Surgeen2026-07-16T00:00:00.000ZHistological Spectrum and Determinants of Survival in Malignant Mesothelioma: Multivariate Analysis from a Five-Year North Indian Tertiary Cancer Center Cohorthttps://www.pharmaradar360.com/article/efficacy-and-safety-of-brensocatib-in-participants-of-asian-race-with-non-cystic-91ea6c8b19a124a9Pharma Surgeen2026-07-16T00:00:00.000ZEfficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trialhttps://www.pharmaradar360.com/article/italian-association-of-nuclear-medicine-molecular-imaging-and-therapy-aimn-pract-d54aee8d696342c3Pharma Surgeen2026-07-16T00:00:00.000ZItalian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for lymphoscintigraphy and sentinel lymph node biopsy in melanomahttps://www.pharmaradar360.com/article/stromal-and-tumoral-claudin-1-expression-in-odontogenic-tumors-correlation-with-bb765174210a4751Pharma Surgeen2026-07-16T00:00:00.000ZStromal and Tumoral Claudin-1 Expression in Odontogenic Tumors: Correlation with β-Catenin and Clinical Outcomeshttps://www.pharmaradar360.com/article/human-umbilical-cord-mesenchymal-stem-cells-in-metabolic-dysfunction-associated-c629ccb74ccad73ePharma Surgeen2026-07-16T00:00:00.000ZHuman Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectiveshttps://www.pharmaradar360.com/article/restless-legs-syndrome-and-mental-health-disturbances-clinical-implications-and-29b9f207c5cad399Pharma Surgeen2026-07-16T00:00:00.000ZRestless Legs Syndrome and Mental Health Disturbances: Clinical Implications and Current Treatment Optionshttps://www.pharmaradar360.com/article/clinical-impact-of-adjuvant-chemotherapy-and-regimen-selection-in-stage-iii-colo-5c6be7c0e02f2baaPharma Surgeen2026-07-16T00:00:00.000ZClinical impact of adjuvant chemotherapy and regimen selection in Stage III colorectal cancer with impaired performance status: a multicenter cohort studyhttps://www.pharmaradar360.com/article/peri-implant-crevicular-fluid-stress-related-biomarkers-and-psychometric-scores-e73c7d637ad1313cPharma Surgeen2026-07-16T00:00:00.000ZPeri-implant crevicular fluid stress-related biomarkers and psychometric scores in peri-implant health and diseasehttps://www.pharmaradar360.com/article/nishida-procedure-versus-single-horizontal-muscle-transposition-in-monocular-ele-635b6ff9174c13d3Pharma Surgeen2026-07-16T00:00:00.000ZNishida procedure versus single horizontal muscle transposition in monocular elevation deficiencyhttps://www.pharmaradar360.com/article/efficacy-and-eeg-ecg-mechanisms-of-tavns-combined-with-teas-for-negative-symptom-3baaae6174223a1fPharma Surgeen2026-07-16T00:00:00.000ZEfficacy and EEG-ECG mechanisms of taVNS combined with TEAS for negative symptoms of schizophrenia: a protocol for a 2 × 2 factorial randomized controlled trialhttps://www.pharmaradar360.com/article/omitting-catheterization-after-ureteroscopic-lithotripsy-a-prospective-multicent-8a5b579aecf985a1Pharma Surgeen2026-07-16T00:00:00.000ZOmitting catheterization after ureteroscopic lithotripsy: a prospective, multicenter, randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-assessment-of-breast-volume-updated-3d-imaging-demonstrates-good-agreem-f859c853908e9a6ePharma Surgeen2026-07-16T00:00:00.000ZClinical assessment of breast volume: updated 3D imaging demonstrates good agreement to MRI measurementshttps://www.pharmaradar360.com/article/gcfh-mda-graph-collaborative-filtering-with-hypergraph-augmentation-for-mirna-dr-857fe72ab15b0598Pharma Surgeen2026-07-16T00:00:00.000ZGCFH-MDA: Graph Collaborative Filtering with Hypergraph Augmentation for MiRNA-Drug Association Predictionhttps://www.pharmaradar360.com/article/congenital-sparse-and-brittle-hair-in-a-child-877abe3542d6efb3Pharma Surgeen2026-07-16T00:00:00.000ZCongenital Sparse and Brittle Hair in a Childhttps://www.pharmaradar360.com/article/kelun-biotech-s-sac-tmt-keytruda-combination-outperforms-standard-first-line-the-dc3de981f801b771Pharma Surgeen2026-07-15T23:55:28.000ZKelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trialhttps://www.pharmaradar360.com/article/lobbying-update-90-000-of-legend-biotech-corporation-lobbying-was-just-disclosed-c21cbeebd93618d2Pharma Surgeen2026-07-15T23:13:00.000ZLobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosedhttps://www.pharmaradar360.com/article/every-baby-in-england-to-get-life-saving-genetic-test-from-birth-865bd144bfa7daffPharma Surgeen2026-07-15T23:01:00.000ZEvery baby in England to get life-saving genetic test from birthhttps://www.pharmaradar360.com/article/transforming-the-pharmaceutical-supply-chain-a-call-to-action-for-uk-pharmacy-bc62a18fd10b4444Pharma Surgeen2026-07-15T22:59:26.000ZTransforming the pharmaceutical supply chain: a call to action for UK pharmacyhttps://www.pharmaradar360.com/article/biotech-s-historic-m-a-run-rate-40f17223ba9e439ePharma Surgeen2026-07-15T22:25:00.000ZBiotech’s historic M&A run ratehttps://www.pharmaradar360.com/article/approval-of-the-issuer-s-statement-pursuant-to-art-103-para-3-of-leg-decree-no-5-4dd8426796132273Pharma Surgeen2026-07-15T22:22:24.000ZApproval of the Issuer’s statement pursuant to art 103 para 3 of Leg Decree no. 58/1998, in connection with the public VTO for all the ordinary shares of Recordati Spa launched by Respighi BidCo Spahttps://www.pharmaradar360.com/article/biotech-bill-aims-to-scrutinize-us-china-ties-9de1965e37bf9862Pharma Surgeen2026-07-15T22:08:39.000ZBiotech: Bill aims to scrutinize US-China tieshttps://www.pharmaradar360.com/article/funding-gap-between-overall-survival-data-and-investor-near-term-expectations-is-5e2f1e17f21914d3Pharma Surgeen2026-07-15T21:43:21.000ZFunding Gap Between Overall Survival Data and Investor Near-Term Expectations Is Stalling Oncology Drug Development, Says Oncolytics Biotech CEO Jared Kellyhttps://www.pharmaradar360.com/article/fda-framework-for-modern-preclinical-drug-development-selectscience-interview-958981d3edcf99b3Pharma Surgeen2026-07-15T20:36:49.000ZFDA framework for modern preclinical drug development - SelectScience interviewhttps://www.pharmaradar360.com/article/cpc-biotech-introduces-one-inch-flow-path-single-use-sterile-disconnect-for-biop-77d80c68a29e0435Pharma Surgeen2026-07-15T20:15:00.000ZCPC Biotech Introduces One-Inch Flow Path, Single-Use Sterile Disconnect for Bioprocessinghttps://www.pharmaradar360.com/article/women-s-health-attracted-record-equity-in-2025-as-companies-share-capital-422518965fff7c03Pharma Surgeen2026-07-15T20:10:05.000ZWomen’s health attracted record equity in 2025 as companies share capitalhttps://www.pharmaradar360.com/article/tarsus-acquires-irenix-medical-adds-late-stage-ocular-antiseptic-e74780e61f78e37ePharma Surgeen2026-07-15T19:48:29.000ZTarsus acquires iRenix Medical, adds late-stage ocular antiseptichttps://www.pharmaradar360.com/article/manufacturing-intelligence-sizing-up-pharma-s-biggest-ai-deals-part-one-342ad4aa08e6ccb1Pharma Surgeen2026-07-15T19:38:04.000ZManufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Onehttps://www.pharmaradar360.com/article/orca-bio-bringing-more-biotech-jobs-to-sacramento-4e32d749795dae9aPharma Surgeen2026-07-15T19:38:00.000ZOrca Bio bringing more biotech jobs to Sacramentohttps://www.pharmaradar360.com/article/consulta-publica-requerimientos-tecnicos-administrativos-e38053654ef2b58bPharma Surgeen2026-07-15T19:19:34.000ZCONSULTA PÚBLICA REQUERIMIENTOS TÉCNICOS ADMINISTRATIVOShttps://www.pharmaradar360.com/article/fda-approves-reytorpyk-for-advanced-breast-cancer-pharmexec-4100ee864540d31bPharma Surgeen2026-07-15T19:15:37.000ZFDA Approves Reytorpyk for Advanced Breast Cancer | PharmExechttps://www.pharmaradar360.com/article/cannara-biotech-love-investor-presentation-summary-6137f1e66f87c77cPharma Surgeen2026-07-15T18:51:51.000ZCannara Biotech (LOVE) Investor presentation Summaryhttps://www.pharmaradar360.com/article/america-must-win-the-biotech-competition-with-china-0078b6e3347fb728Pharma Surgeen2026-07-15T18:51:47.000ZAmerica must win the biotech competition with Chinahttps://www.pharmaradar360.com/article/why-veraxa-biotech-vrxa-could-benefit-more-than-others-from-ai-s-growing-impact-bf2755c1a177a309Pharma Surgeen2026-07-15T18:44:42.000ZWhy VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&Dhttps://www.pharmaradar360.com/article/siya-goyal-family-s-spice-shop-shut-over-food-safety-breach-5132fb5c4ddbd0ebPharma Surgeen2026-07-15T18:29:34.000ZSiya Goyal family's spice shop shut over food safety breachhttps://www.pharmaradar360.com/article/proposed-legislation-aims-to-lower-prescription-drug-costs-reduce-barriers-for-d-cd610f6e9cc92703Pharma Surgeen2026-07-15T18:17:00.000ZProposed legislation aims to lower prescription drug costs, reduce barriers for drug manufacturershttps://www.pharmaradar360.com/article/drug-shortages-a426e4f99d62d81aPharma Surgeen2026-07-15T18:12:35.000ZDrug Shortageshttps://www.pharmaradar360.com/article/india-s-sun-pharma-wins-south-africa-approval-to-launch-generic-ozempic-e07e1258d3a6fd4aPharma Surgeen2026-07-15T17:46:08.000ZIndia's Sun Pharma wins South Africa approval to launch generic Ozempichttps://www.pharmaradar360.com/article/pharmaceutical-method-of-use-claims-after-teva-v-eli-lilly-and-in-re-xencor-writ-ae847e2d85c8601fPharma Surgeen2026-07-15T17:33:57.000ZPharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genushttps://www.pharmaradar360.com/article/fda-finalizes-guidance-on-clinical-trial-design-for-psychedelic-drug-development-7618434735a9d05bPharma Surgeen2026-07-15T17:18:56.000ZFDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Developmenthttps://www.pharmaradar360.com/article/pharmaceutical-m-a-activity-gains-momentum-in-brazil-b8fc925db0e2528dPharma Surgeen2026-07-15T16:38:04.000ZPharmaceutical M&A activity gains momentum in Brazilhttps://www.pharmaradar360.com/article/tegoprubart-sustains-increased-egfr-longterm-compared-to-tacrolimus-be16f06d6881492aPharma Surgeen2026-07-15T16:15:46.000ZTegoprubart Sustains Increased eGFR Longterm Compared to Tacrolimushttps://www.pharmaradar360.com/article/all-12-tegoprubart-recipients-off-external-insulin-following-islet-implant-in-pi-0915a22e754731f4Pharma Surgeen2026-07-15T16:15:18.000ZAll 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Studyhttps://www.pharmaradar360.com/article/cannara-biotech-reports-q3-2026-results-full-earnings-call-transcript-9aa3d94668d043c3Pharma Surgeen2026-07-15T15:58:43.000ZCannara Biotech Reports Q3 2026 Results: Full Earnings Call Transcripthttps://www.pharmaradar360.com/article/fda-finalizes-guidance-on-psychedelic-drug-clinical-trial-design-and-safety-cons-43f626bb37f0f589Pharma Surgeen2026-07-15T15:57:34.000ZFDA finalizes guidance on psychedelic drug clinical trial design and safety considerationshttps://www.pharmaradar360.com/article/braveheart-attovia-join-next-wave-of-biotech-ipos-004367ddce29b346Pharma Surgeen2026-07-15T15:53:55.000ZBraveheart, Attovia join next wave of biotech IPOshttps://www.pharmaradar360.com/article/cervomed-reports-positive-clinical-biomarker-and-mri-data-for-neflamapimod-at-aa-1728d74cea19da4fPharma Surgeen2026-07-15T15:51:26.000ZCervoMed Reports Positive Clinical, Biomarker and MRI Data for Neflamapimod at AAIC 2026https://www.pharmaradar360.com/article/q-a-how-pharma-3pl-is-evolving-beyond-the-pallet-be2e59931753a28ePharma Surgeen2026-07-15T15:49:50.000ZQ&A: How Pharma 3PL Is Evolving Beyond the Pallethttps://www.pharmaradar360.com/article/adhd-medicines-prescriptions-rose-again-in-2025-8c8f30c58bd50c8fPharma Surgeen2026-07-15T15:48:54.000ZADHD medicines prescriptions rose again in 2025https://www.pharmaradar360.com/article/johnson-fistel-pllp-investigates-claims-on-behalf-of-e738e7669e497667Pharma Surgeen2026-07-15T15:33:28.000ZJohnson Fistel, PLLP Investigates Claims on Behalf ofhttps://www.pharmaradar360.com/article/astrazeneca-licenses-novel-oral-egfr-inhibitor-for-1-5bn-f61e6125381427bePharma Surgeen2026-07-15T15:30:05.000ZAstraZeneca licenses novel oral EGFR inhibitor for $1.5bnhttps://www.pharmaradar360.com/article/stoppering-machines-market-growth-outlook-to-2035-automation-and-biologics-fuel-2df6d3b9f8473491Pharma Surgeen2026-07-15T15:16:12.000ZStoppering Machines Market Growth Outlook to 2035: Automation and Biologics Fuel Demand - News and Statisticshttps://www.pharmaradar360.com/article/soficitinib-icp-332-meets-primary-endpoint-in-phase-3-trial-for-moderate-to-seve-1e06ae02dd554ec7Pharma Surgeen2026-07-15T15:11:49.000ZSoficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe ADhttps://www.pharmaradar360.com/article/celcuity-s-breast-cancer-drug-approved-its-first-6bbba6e0d08aa5a4Pharma Surgeen2026-07-15T15:09:37.000ZCelcuity’s breast cancer drug approved, its firsthttps://www.pharmaradar360.com/article/pitt-signs-deal-with-biotech-firm-to-study-mitochondria-in-space-and-long-covid-a36d20a6cf68f495Pharma Surgeen2026-07-15T15:08:56.000ZPitt signs deal with biotech firm to study mitochondria in space and long Covidhttps://www.pharmaradar360.com/article/the-glp-1-boom-created-a-2-billion-opening-in-aesthetics-one-preclinical-biotech-0e28cbf91787f51dPharma Surgeen2026-07-15T15:01:00.000ZThe GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.https://www.pharmaradar360.com/article/big-pharma-backed-advancell-flush-with-315m-series-d-ready-to-put-radiotherapy-p-323618edfa7cd7e3Pharma Surgeen2026-07-15T14:50:46.000ZBig Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metalhttps://www.pharmaradar360.com/article/doj-s-bulk-sensitive-personal-data-rule-a-cross-border-compliance-imperative-for-2b077597d354c170Pharma Surgeen2026-07-15T14:46:55.000ZDOJ’s Bulk Sensitive Personal Data Rule: A Cross-Border Compliance Imperative for the Life Sciences Industryhttps://www.pharmaradar360.com/article/katalyze-ai-raises-10-5m-to-build-the-agentic-operating-system-for-pharmaceutica-d0d0e926641d8721Pharma Surgeen2026-07-15T14:41:17.000ZKatalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/j-j-axes-eye-disease-gene-therapy-after-key-phase-2b-readout-6ce99a166ed86e76Pharma Surgeen2026-07-15T14:26:53.000ZJ&J axes eye disease gene therapy after key phase 2b readouthttps://www.pharmaradar360.com/article/why-this-biotech-stock-with-its-first-fda-approval-just-crashed-by-double-digits-32f9d1445f954682Pharma Surgeen2026-07-15T14:26:00.000ZWhy This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digitshttps://www.pharmaradar360.com/article/treating-a-rare-form-of-obesity-caused-by-brain-injury-462f2739e8cf1a74Pharma Surgeen2026-07-15T14:24:27.000ZTreating a Rare Form of Obesity Caused by Brain Injuryhttps://www.pharmaradar360.com/article/kelun-scores-sac-tmt-win-in-first-line-nsclc-population-missing-from-merck-s-mas-16260c39ae91028cPharma Surgeen2026-07-15T14:20:41.000ZKelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 programhttps://www.pharmaradar360.com/article/tukaram-mundhe-effect-fda-turns-to-ai-for-instant-food-adulteration-fake-med-com-22c8b6fd3870bdedPharma Surgeen2026-07-15T14:19:50.000ZTukaram Mundhe Effect: FDA Turns To AI For Instant Food Adulteration, Fake Med Complaintshttps://www.pharmaradar360.com/article/manufacturing-intelligence-sizing-up-pharma-s-biggest-ai-deals-part-one-fd009a9aff191c9cPharma Surgeen2026-07-15T14:19:19.000ZManufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Onehttps://www.pharmaradar360.com/article/china-targets-pharmaceutical-supply-chains-in-coordinated-fraud-inspections-f6023655e9bafec9Pharma Surgeen2026-07-15T14:11:51.000ZChina targets pharmaceutical supply chains in coordinated fraud inspectionshttps://www.pharmaradar360.com/article/merck-to-present-hiv-treatment-trial-data-at-aids-conference-by-investing-com-9583a342e41b94e1Pharma Surgeen2026-07-15T14:06:22.000ZMerck to present HIV treatment trial data at AIDS conference By Investing.comhttps://www.pharmaradar360.com/article/review-body-on-doctors-and-dentists-remuneration-remit-letter-2027-to-2028-8c7b12beaeebe78aPharma Surgeen2026-07-15T13:57:34.000ZReview Body on Doctors' and Dentists' Remuneration remit letter: 2027 to 2028https://www.pharmaradar360.com/article/nhs-pay-review-body-remit-letter-2027-to-2028-6a81d0c8fb23dc5aPharma Surgeen2026-07-15T13:57:31.000ZNHS Pay Review Body remit letter: 2027 to 2028https://www.pharmaradar360.com/article/senior-salaries-review-body-remit-letter-2027-to-2028-4b88fe34e0bf692bPharma Surgeen2026-07-15T13:57:27.000ZSenior Salaries Review Body remit letter: 2027 to 2028https://www.pharmaradar360.com/article/clinical-trials-for-medicines-ending-a-clinical-trial-e20295b3d49b69b5Pharma Surgeen2026-07-15T13:50:10.000ZClinical trials for medicines: ending a clinical trialhttps://www.pharmaradar360.com/article/gsk-completes-acquisition-of-nuvalent-inc-bb9f750c34ca10f4Pharma Surgeen2026-07-15T13:40:11.000ZGSK completes acquisition of Nuvalent, Inc.https://www.pharmaradar360.com/article/smarter-data-faster-decisions-how-biotech-funding-pressures-are-reshaping-clinic-bd8b5260d7a79d75Pharma Surgeen2026-07-15T13:39:08.000ZSmarter data, faster decisions: How biotech funding pressures are reshaping clinical developmenthttps://www.pharmaradar360.com/article/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-52e0d33b2719579dPharma Surgeen2026-07-15T13:37:57.000ZNew autologous T cell therapy offers hope for children with brain tumorshttps://www.pharmaradar360.com/article/explained-7-major-fda-crackdowns-in-pune-under-tukaram-mundhe-from-blood-banks-t-9aca8b1007caf94aPharma Surgeen2026-07-15T13:35:50.000ZExplained: 7 Major FDA Crackdowns In Pune Under Tukaram Mundhe, From Blood Banks To Counterfeit Cetaphil Skinhttps://www.pharmaradar360.com/article/akeso-opens-u-s-phase-ii-trial-for-pd-1-ctla-4-bispecific-42106c875062cb91Pharma Surgeen2026-07-15T13:30:48.000ZAkeso Opens U.S. Phase II Trial for PD-1/CTLA-4 Bispecifichttps://www.pharmaradar360.com/article/american-airlines-cargo-builds-pharma-corridor-connecting-europe-and-the-us-0ded2e328f0fe503Pharma Surgeen2026-07-15T13:27:41.000ZAmerican Airlines Cargo builds pharma corridor connecting Europe and the UShttps://www.pharmaradar360.com/article/aaic26-the-role-of-biomarkers-in-primary-care-and-early-diagnostics-5a68a22c09a0dee2Pharma Surgeen2026-07-15T13:25:18.000ZAAIC26: The role of biomarkers in primary care and early diagnosticshttps://www.pharmaradar360.com/article/global-biopharmaceutical-ceos-response-to-reforms-introduced-in-germany-22d462cb40892ca1Pharma Surgeen2026-07-15T13:14:50.000ZGlobal biopharmaceutical CEOs response to reforms introduced in Germanyhttps://www.pharmaradar360.com/article/fda-activity-round-up-july-2026-8f9dcbf0475c8f26Pharma Surgeen2026-07-15T13:04:19.000ZFDA Activity Round Up – July 2026https://www.pharmaradar360.com/article/fda-drug-approval-affects-healthcare-around-the-world-but-political-shortcuts-co-f9033f1952aabaeaPharma Surgeen2026-07-15T13:04:08.000ZFDA drug approval affects healthcare around the world, but political shortcuts could hurt the agency’s international reputationhttps://www.pharmaradar360.com/article/botulinum-toxin-type-a-products-updated-warnings-regarding-risk-of-iatrogenic-bo-fd0eebf65ce9495cPharma Surgeen2026-07-15T13:00:15.000ZBotulinum toxin type A products: updated warnings regarding risk of iatrogenic botulismhttps://www.pharmaradar360.com/article/cellular-intelligence-expands-leadership-team-with-seasoned-ai-and-biotech-indus-d48bfba9c9d35885Pharma Surgeen2026-07-15T13:00:00.000ZCellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executiveshttps://www.pharmaradar360.com/article/kelun-biotech-reports-phase-iii-success-for-sac-tmt-combination-in-nsclc-07ad02e41eb33b24Pharma Surgeen2026-07-15T12:57:05.000ZKelun-Biotech reports Phase III success for sac-TMT combination in NSCLChttps://www.pharmaradar360.com/article/acrp-certification-exams-transition-to-ich-e6-r3-on-july-15-65c21fd4115ed5bePharma Surgeen2026-07-15T12:48:26.000ZACRP Certification Exams Transition to ICH E6(R3) on July 15https://www.pharmaradar360.com/article/a-weight-loss-revolution-is-reshaping-bodies-this-preclinical-biotech-wants-to-b-c395289e70b82450Pharma Surgeen2026-07-15T12:45:10.000ZA Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Nexthttps://www.pharmaradar360.com/article/atrium-therapeutics-launches-phase-1-2-trial-for-atr-1072-f198b77f4f7587c7Pharma Surgeen2026-07-15T12:22:28.000ZAtrium Therapeutics Launches Phase 1/2 Trial for ATR 1072https://www.pharmaradar360.com/article/fda-drug-approval-affects-healthcare-around-the-world-but-political-shortcuts-co-d894081a500d9faePharma Surgeen2026-07-15T12:09:59.000ZFDA drug approval affects healthcare around the world, but political shortcuts could hurt the agency’s international reputationhttps://www.pharmaradar360.com/article/surveillance-of-bloodstream-infections-in-intensive-care-units-england-2025-80263adc565cf040Pharma Surgeen2026-07-15T12:07:26.000ZSurveillance of bloodstream infections in intensive care units, England: 2025https://www.pharmaradar360.com/article/segunda-reunion-de-2026-del-comite-de-seguridad-de-medicamentos-veterinarios-y-d-624354da3256518ePharma Surgeen2026-07-15T12:06:01.000ZSegunda reunión de 2026 del Comité de Seguridad de Medicamentos Veterinarios y del Comité Técnico del Sistema Español de Farmacovigilancia de Medicamentos Veterinarioshttps://www.pharmaradar360.com/article/guidance-medical-devices-list-of-uk-approved-bodies-282ee766885a0ff9Pharma Surgeen2026-07-15T12:03:34.000ZGuidance: Medical devices: list of UK approved bodieshttps://www.pharmaradar360.com/article/lakewood-amedex-biotherapeutics-announces-preclinical-safety-data-supporting-cli-30413b8bb4d93b3aPharma Surgeen2026-07-15T12:02:00.000ZLakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gelhttps://www.pharmaradar360.com/article/brief-cannara-biotech-q3-eps-cad-0-05-1c90390c9dcaf648Pharma Surgeen2026-07-15T12:01:03.000ZBRIEF-Cannara Biotech Q3 EPS CAD 0.05https://www.pharmaradar360.com/article/presource-kits-containing-teleflex-pilling-wecksorb-neurosponge-1d16009ebbb12800Pharma Surgeen2026-07-15T12:00:00.000ZPresource ®Kits containing Teleflex Pilling® Wecksorb Neurospongehttps://www.pharmaradar360.com/article/leoni-plus-a228b4b88b6a3b33Pharma Surgeen2026-07-15T12:00:00.000ZLeoni Plushttps://www.pharmaradar360.com/article/atyr-s-44-patient-analysis-shows-123-8-ml-lung-function-benefit-99a6af3ccf1a9329Pharma Surgeen2026-07-15T12:00:00.000ZaTyr's 44-patient analysis shows 123.8 mL lung-function benefithttps://www.pharmaradar360.com/article/cannara-biotech-love-investor-presentation-summary-39d7ae2a8ad589d9Pharma Surgeen2026-07-15T11:58:57.000ZCannara Biotech (LOVE) Investor presentation Summaryhttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-clinical-trials-regulations-transitional-arrangeme-9dc39551d9dd0eb7Pharma Surgeen2026-07-15T11:54:40.000ZClinical trials for medicines: Clinical Trials Regulations transitional arrangementshttps://www.pharmaradar360.com/article/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgi-7c709b419524f2edPharma Surgeen2026-07-15T11:45:00.000ZIntensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)https://www.pharmaradar360.com/article/anmat-simplifica-el-marco-regulatorio-para-las-modificaciones-posteriores-al-reg-176f5c53d174e9ccPharma Surgeen2026-07-15T11:32:08.000ZANMAT simplifica el marco regulatorio para las modificaciones posteriores al registro de especialidades medicinales de origen biológicohttps://www.pharmaradar360.com/article/biotech-listings-back-with-a-bang-nordic-player-among-record-breaking-companies-b6eb0785bc8604fePharma Surgeen2026-07-15T11:31:07.000ZBiotech listings back with a bang – Nordic player among record-breaking companieshttps://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-reports-657m-carvykti-sales-c209dd99deb2e56aPharma Surgeen2026-07-15T11:30:38.000ZLegend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI saleshttps://www.pharmaradar360.com/article/briacell-taps-fujifilm-to-make-breast-cancer-cell-therapy-ba16bf9dc4290f2aPharma Surgeen2026-07-15T11:30:00.000ZBriaCell Taps FUJIFILM to Make Breast Cancer Cell Therapyhttps://www.pharmaradar360.com/article/a16z-backed-heart-drug-biotech-braveheart-files-for-nasdaq-ipo-230dae7b6be146dePharma Surgeen2026-07-15T11:17:15.000ZA16z-Backed Heart Drug Biotech Braveheart Files for Nasdaq IPOhttps://www.pharmaradar360.com/article/jim-cramer-crowns-one-surging-sector-the-hottest-in-the-market-3481ed5d2252e0bcPharma Surgeen2026-07-15T11:17:00.000ZJim Cramer crowns one surging sector the hottest in the markethttps://www.pharmaradar360.com/article/british-sign-language-bsl-5-year-plan-department-of-health-and-social-care-30cc27cd2ce930d6Pharma Surgeen2026-07-15T11:13:31.000ZBritish Sign Language (BSL) 5-year plan: Department of Health and Social Carehttps://www.pharmaradar360.com/article/are-you-the-new-ceo-of-swiss-biotech-association-97fbb89332e16c84Pharma Surgeen2026-07-15T11:11:53.000ZAre you the new CEO of Swiss Biotech Association?https://www.pharmaradar360.com/article/top-10-hydroxy-propyl-methyl-cellulose-exporter-from-china-at-cphi-china-2026-99f80231afdaf3aePharma Surgeen2026-07-15T11:06:51.000ZTop 10 Hydroxy Propyl Methyl Cellulose Exporter from China at CPhI China 2026https://www.pharmaradar360.com/article/up-to-90-of-women-reported-better-hair-coverage-by-month-6-35d10721c905cc57Pharma Surgeen2026-07-15T11:02:16.000ZUp to 90% of women reported better hair coverage by Month 6https://www.pharmaradar360.com/article/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-bd4ef0e000a66049Pharma Surgeen2026-07-15T11:00:00.000ZMerck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026https://www.pharmaradar360.com/article/johnson-johnson-shares-fall-despite-better-than-expected-results-724a90bfb470a21ePharma Surgeen2026-07-15T10:56:30.000ZJohnson & Johnson shares fall despite better-than-expected resultshttps://www.pharmaradar360.com/article/astrazeneca-pays-up-to-1-5bn-to-license-dizal-pharma-s-lung-cancer-drug-7352fa87037eec86Pharma Surgeen2026-07-15T10:52:30.000ZAstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drughttps://www.pharmaradar360.com/article/sichuan-kelun-biotech-biopharmaceutical-and-harbour-biomed-receive-nmpa-approval-9c99f222ca05821aPharma Surgeen2026-07-15T10:50:48.000ZSichuan Kelun-Biotech Biopharmaceutical and Harbour Biomed Receive Nmpa Approval of Ind Application for Skb575/Hbm7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-50a0267f52b4a72cPharma Surgeen2026-07-15T10:45:00.000ZKEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapyhttps://www.pharmaradar360.com/article/biogen-shares-slide-as-diranersen-data-raise-dosing-question-00a9d85654d2a198Pharma Surgeen2026-07-15T10:42:57.000ZBiogen shares slide as diranersen data raise dosing questionhttps://www.pharmaradar360.com/article/fda-suspends-licence-of-salunkhe-vihar-road-cafe-over-hygiene-lapses-4c8b72e95af712e3Pharma Surgeen2026-07-15T10:41:38.000ZFDA suspends licence of Salunkhe Vihar Road cafe over hygiene lapseshttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-collection-verification-and-reporting-of-safety-ev-f9fb7893827ee468Pharma Surgeen2026-07-15T10:36:39.000ZClinical trials for medicines: collection, verification and reporting of safety eventshttps://www.pharmaradar360.com/article/prac-6-9-2026-b775a7fed8b8bd76Pharma Surgeen2026-07-15T10:31:50.000ZΚύρια σημεία συνεδρίασης της Επιτροπής Αξιολόγησης Κινδύνου Φαρμακοεπαγρύπνησης (PRAC), 6 – 9 Ιουλίου 2026https://www.pharmaradar360.com/article/government-and-joe-wicks-support-families-to-stay-active-514c95d4f74fc5d4Pharma Surgeen2026-07-15T10:29:00.000ZGovernment and Joe Wicks support families to stay activehttps://www.pharmaradar360.com/article/sinovac-biotech-nasdaq-sva-extends-55-per-share-dividend-deadline-7d3cd79fee7565aaPharma Surgeen2026-07-15T10:10:01.000ZSinovac Biotech (NASDAQ: SVA) extends $55 per share dividend deadlinehttps://www.pharmaradar360.com/article/corporate-report-medicines-and-healthcare-products-regulatory-agency-annual-repo-4738f50190473de0Pharma Surgeen2026-07-15T10:04:00.000ZCorporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2025 to 2026https://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-announce-nmpa-approval-of-ind-application-for-h-7c5e7d6e53eee0ccPharma Surgeen2026-07-15T10:01:00.000ZHarbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-s-eb7b12e2b66a8faePharma Surgeen2026-07-15T10:00:00.000ZKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-modifying-a-clinical-trial-approval-4b4a6047f9614fbaPharma Surgeen2026-07-15T09:58:11.000ZClinical trials for medicines: modifying a clinical trial approvalhttps://www.pharmaradar360.com/article/a-complete-guide-to-pharmaceutical-ingredients-serum-pharma-s-apis-plant-extract-6b6ab8b530c435bbPharma Surgeen2026-07-15T09:30:00.000ZA Complete Guide to Pharmaceutical Ingredients: Serum Pharma’s APIs, Plant Extracts & Nutraceutical Solutionshttps://www.pharmaradar360.com/article/is-definium-therapeutics-inc-dftx-stock-a-biotech-opportunity-after-positive-dt1-0663c708e471fe9dPharma Surgeen2026-07-15T09:24:34.000ZIs Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?https://www.pharmaradar360.com/article/le-leem-finalise-sa-gouvernance-et-se-mobilise-pour-les-grandes-echeances-politi-29917f1e565550b7Pharma Surgeen2026-07-15T09:22:53.000ZLe Leem finalise sa gouvernance et se mobilise pour les grandes échéances politiques de santé à venirhttps://www.pharmaradar360.com/article/pathogen-genomics-at-porton-down-a47255a8a5e18febPharma Surgeen2026-07-15T09:20:46.000ZPathogen genomics at Porton Downhttps://www.pharmaradar360.com/article/zydus-lifesciences-seals-150-million-sterling-biotech-deal-f7d126b357fa04a4Pharma Surgeen2026-07-15T09:12:42.000ZZydus Lifesciences seals $150 million Sterling Biotech dealhttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-15T09:00:05.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/framework-agreement-between-dhsc-and-the-uk-health-security-agency-2026-to-2029-a07733552c8962cePharma Surgeen2026-07-15T09:00:00.000ZFramework agreement between DHSC and the UK Health Security Agency: 2026 to 2029https://www.pharmaradar360.com/article/hhs-and-fda-respond-to-dea-s-action-on-kratom-related-products-a2d58e5c5f700537Pharma Surgeen2026-07-15T09:00:00.000ZHHS and FDA Respond to DEA’s Action on Kratom-Related Productshttps://www.pharmaradar360.com/article/harel-insurance-investments-financial-services-ltd-increases-position-in-teva-ph-15ed565596b69f92Pharma Surgeen2026-07-15T08:38:52.000ZHarel Insurance Investments & Financial Services Ltd. Increases Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/a-new-biotech-startup-tries-to-tackle-obesity-but-not-in-the-way-you-might-expec-afdfee9cabfae5eaPharma Surgeen2026-07-15T08:34:41.000ZA new biotech startup tries to tackle obesity, but not in the way you might expecthttps://www.pharmaradar360.com/article/biotech-firm-that-went-viral-for-plans-to-create-nonsentient-humanoids-for-organ-3d03aa2c88a2b234Pharma Surgeen2026-07-15T08:34:00.000ZBiotech firm that went viral for plans to create 'nonsentient humanoids' for organ harvesting now says it was never truehttps://www.pharmaradar360.com/article/ukhsa-flusurvey-surveillance-system-9eb06a6a8ee4950aPharma Surgeen2026-07-15T08:30:13.000ZUKHSA FluSurvey surveillance systemhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-15T08:30:13.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-95d573354d6fb70dPharma Surgeen2026-07-15T08:30:13.000ZUK Clinical Research Delivery key performance indicatorshttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-4b8ae69acc200783Pharma Surgeen2026-07-15T08:30:11.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/it-looks-done-common-bbq-blunders-and-how-to-avoid-them-ac5818a1039bd58aPharma Surgeen2026-07-15T08:30:11.000Z'It looks done': Common BBQ blunders and how to avoid themhttps://www.pharmaradar360.com/article/bloodborne-virus-bbv-related-infection-control-breaches-management-toolkit-1288ed113665206cPharma Surgeen2026-07-15T08:30:10.000ZBloodborne virus (BBV) related infection control breaches: management toolkithttps://www.pharmaradar360.com/article/tuberculosis-in-england-2025-report-c1ff658160421e4bPharma Surgeen2026-07-15T08:21:59.000ZTuberculosis in England, 2025 reporthttps://www.pharmaradar360.com/article/la-aemps-actualiza-su-carta-de-servicios-para-el-periodo-2026-2029-4a761197b452f87fPharma Surgeen2026-07-15T08:17:15.000ZLa AEMPS actualiza su Carta de Servicios para el periodo 2026-2029https://www.pharmaradar360.com/article/dutch-innovative-pharma-adding-8-5-billion-to-economy-7817d96798d4c09ePharma Surgeen2026-07-15T08:15:51.000ZDutch innovative pharma adding €8.5 billion to economyhttps://www.pharmaradar360.com/article/attovia-files-for-ipo-to-take-on-sanofi-and-regeneron-s-dupixent-f4d053726a21cbd8Pharma Surgeen2026-07-15T08:09:32.000ZAttovia files for IPO to take on Sanofi and Regeneron’s Dupixenthttps://www.pharmaradar360.com/article/diversify-wealth-management-llc-buys-54-488-shares-of-teva-pharmaceutical-indust-4888447e4cffe6a2Pharma Surgeen2026-07-15T07:52:32.000ZDiversify Wealth Management LLC Buys 54,488 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/i-i-startup-attovia-files-to-go-public-as-biotech-listings-momentum-builds-b612961afb583fb9Pharma Surgeen2026-07-15T07:46:00.000ZI&I startup Attovia files to go public as biotech listings momentum buildshttps://www.pharmaradar360.com/article/biotech-growth-trust-gains-19-2-in-june-outperforms-benchmark-06d44d171ad17184Pharma Surgeen2026-07-15T07:31:27.000ZBiotech Growth Trust Gains 19.2% In June, Outperforms Benchmarkhttps://www.pharmaradar360.com/article/imdylltra-becab08624a27dc1Pharma Surgeen2026-07-15T07:29:38.000ZIMDYLLTRAhttps://www.pharmaradar360.com/article/hemab-s-sutacimig-cuts-bleeds-84-in-phase-2-glanzmann-thrombasthenia-study-3d9d7d9e5d4ec704Pharma Surgeen2026-07-15T07:09:18.000ZHemab’s Sutacimig Cuts Bleeds 84% in Phase 2 Glanzmann Thrombasthenia Studyhttps://www.pharmaradar360.com/article/oric-initiates-himalayas-1-phase-3-trial-of-rinzimetostat-for-mcrpc-4ed4382f0766028fPharma Surgeen2026-07-15T07:09:18.000ZORIC Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat for mCRPChttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-reports-9-7-june-nav-increase-66b94ddac3f25c05Pharma Surgeen2026-07-15T07:03:49.000ZRTW Biotech Opportunities reports 9.7% June NAV increasehttps://www.pharmaradar360.com/article/formulation-freedom-in-clinical-development-why-fill2weight-matters-c2bd55340fe6b99dPharma Surgeen2026-07-15T07:00:38.000ZFormulation freedom in clinical development: Why Fill2Weight mattershttps://www.pharmaradar360.com/article/epoch-biotech-highlights-new-preclinical-data-for-apoe-christchurch-mimetic-anti-4f8bdc03ab40700bPharma Surgeen2026-07-15T07:00:00.000ZEpoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approachhttps://www.pharmaradar360.com/article/kelun-biotech-s-sac-tmt-plus-pembrolizumab-hits-primary-endpoint-in-pd-l1-negati-16c13f87c3493585Pharma Surgeen2026-07-15T06:59:18.000ZKelun-Biotech’s sac-TMT Plus Pembrolizumab Hits Primary Endpoint in PD-L1-Negative NSCLC